Healthcare
Quest Diagnostics Incorporated(DGX)
Live Price
Offline$195.00
-1.40% today
1Y Change
+13.69%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $21.13B
- Revenue Growth
- +11.8%
- EPS Growth
- +13.7%
- Dividend Yield
- 1.7%
Coverage: 250 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Quest Diagnostics Incorporated (DGX) is a Healthcare stock with a market cap of $21.13B and listed on NYSE. The stock last traded around $195.00 and up 13.7% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of +11.8%, EPS growth of +13.7%, a dividend yield of 1.7%. What stands out right now is revenue +11.8%, EPS +13.7%, free cash flow +49.5% with operating margin 14.3% and ROIC 8.1%. The dividend is present but secondary, with a yield around 1.7%. Valuation is more restrained than many high-expectation growth names at P/E 20.5 and price/sales 1.9. Stock Foundry combines DGX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+11.8% vs +7.6% peer median
Operating Margin
Below sector median
+14.3% vs +19.4% peer median
P/E
Below sector median
20.5 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +11.8% and EPS at +13.7%, with operating margin around 14.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.7%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.9% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 21, 2026 | โ | -0.5% | -4.9% | -7.1% |
2026 Feb 10, 2026 | +2.5% | +1.9% | -0.5% | -2.3% |
2025 Oct 21, 2025 | +4.0% | -1.9% | -3.4% | +0.4% |
Benchmark Edge
DGX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
DGX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
DGX Max Drawdown
-11.94%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for DGX and SPY.
Company Overview
Quest Diagnostics Incorporated
New York Stock Exchange
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
- Leadership
- James E. Davis
- IPO Date
- Dec 17, 1996
- Employees
- 55.0k
- Street Address
- 500 Plaza Drive
- Mailing
- Secaucus, NJ, 07094
- Region
- Secaucus, NJ, US
- Reporting Currency
- USD
- Investor Line
- 973 520 2700
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 20.5
- EV/EBITDA
- 14.0
- Price/Sales
- 1.9
- Price/Book
- 2.8
Growth
- Revenue
- +11.8%
- EPS
- +13.7%
- Free Cash Flow
- +49.5%
Profitability
- Gross Margin
- 33.2%
- Operating Margin
- 14.3%
- Net Margin
- 9.1%
- ROE
- 14.1%
- ROIC
- 8.1%
Balance Sheet
- Debt/Equity
- 0.95
- Current Ratio
- 1.18
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.